Vimarsana
Biggest News Aggregation in the World

Page 19 - Repligen Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Repligen Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Repligen Daily Today - Breaking & Trending Today

Repligen (NASDAQ:RGEN) PT Lowered to $165.00 - Vimarsana News

Repligen (NASDAQ:RGEN) PT Lowered to $165.00

Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by research analysts at Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a report issued on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 4.94% from the company’s current price. RGEN has been the subject of several other reports. […]

Craig Hallum Lowers Repligen (NASDAQ:RGEN) Price Target to $207.00 - Vimarsana News

Craig Hallum Lowers Repligen (NASDAQ:RGEN) Price Target to $207.00

Repligen (NASDAQ:RGEN – Get Rating) had its price target decreased by Craig Hallum from $220.00 to $207.00 in a report released on Wednesday, The Fly reports. Craig Hallum’s target price points to a potential upside of 31.65% from the stock’s current price. Several other research analysts have also recently commented on the company. SVB Leerink […]

Q3 2023 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Reduced by Analyst - Vimarsana News

Q3 2023 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Reduced by Analyst

Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair reduced their Q3 2023 earnings estimates for Repligen in a research report issued on Wednesday, May 3rd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, down from their prior forecast […]

Repligen (NASDAQ:RGEN) Issues Earnings Results - Vimarsana News

Repligen (NASDAQ:RGEN) Issues Earnings Results

Repligen (NASDAQ:RGEN – Get Rating) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05, Briefing.com reports. Repligen had a return on equity of 10.31% and a net margin of 23.20%. The company had revenue of $182.70 million during the quarter, […]

Repligen (NASDAQ:RGEN) Price Target Cut to $210.00 by Analysts at Stifel Nicolaus - Vimarsana News

Repligen (NASDAQ:RGEN) Price Target Cut to $210.00 by Analysts at Stifel Nicolaus

Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by Stifel Nicolaus from $225.00 to $210.00 in a research note issued to investors on Wednesday, The Fly reports. A number of other brokerages also recently weighed in on RGEN. StockNews.com initiated coverage on Repligen in a report on Thursday, March 16th. They issued a […]